KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Long-Term Investments: 2009-2025

Historic Long-Term Investments for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $512.9 million.

  • Biomarin Pharmaceutical's Long-Term Investments fell 8.73% to $512.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $512.9 million, marking a year-over-year decrease of 8.73%. This contributed to the annual value of $521.2 million for FY2024, which is 14.71% down from last year.
  • Biomarin Pharmaceutical's Long-Term Investments amounted to $512.9 million in Q3 2025, which was up 0.85% from $508.6 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Long-Term Investments ranged from a high of $620.6 million in Q1 2024 and a low of $321.1 million during Q1 2021.
  • Over the past 3 years, Biomarin Pharmaceutical's median Long-Term Investments value was $521.2 million (recorded in 2024), while the average stood at $515.9 million.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Long-Term Investments tumbled by 34.26% in 2022 and then surged by 83.06% in 2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Long-Term Investments (Quarterly) stood at $507.8 million in 2021, then tumbled by 34.26% to $333.8 million in 2022, then surged by 83.06% to $611.1 million in 2023, then fell by 14.71% to $521.2 million in 2024, then dropped by 8.73% to $512.9 million in 2025.
  • Its last three reported values are $512.9 million in Q3 2025, $508.6 million for Q2 2025, and $506.7 million during Q1 2025.